- Patients with metastatic, late-stage cancers
- 10 of 11 patients showing no disease progression following 3-months treatment with NOX66 in combination with low-dose carboplatin
- Well-tolerated drug combination
20 November 2017, Sydney: Noxopharm is pleased to release interim data from its first-in-human study of NOX66 being conducted in Georgia. The data was presented to the European Society of Medical Oncology Asia conference in Singapore on 18 November 2017.
The data shows promising outcomes both in terms of safety and disease control in patients receiving NOX66 in combination with a low dose of carboplatin. The Company notes that this is interim data, with the majority of patients yet to reach the end of the study, and in particular yet to include additional data from the higher dose of NOX66 considered by the Company to be the final clinical dose.
For further information please download PDF attached:
Download this document
